Cookie Einstellungen
Diese Webseite verwendet ausschließlich notwendige Cookies, die für die Funktion erforderlich sind. Marketing- und Statistik-Cookies kommen nicht zum Einsatz. Weitere Informationen finden Sie in unserer Datenschutzerklärung.
 Notwendig   Details einblenden
      OK      
Bitte logge Dich ein, um diese Funktion zu nutzen!
      OK      
x

RECORDATI Aktie

 >RECORDATI Aktienkurs 
53.85 EUR    +0.8%    (Tradegate)
Ask: 54.15 EUR / 100 Stück
Bid: 53.6 EUR / 100 Stück
Tagesumsatz: 50 Stück
Realtime Kurs von 8 bis 22 Uhr!
RECORDATI Aktie über LYNX handeln
>RECORDATI Performance
1 Woche: +0,5%
1 Monat: +2,3%
3 Monate: +7,1%
6 Monate: +4,7%
1 Jahr: +9,6%
laufendes Jahr: +6,0%
>RECORDATI Aktie
Name:  RECORDATI SPA EO -,125
Land:  Italien
Sektor:  Gesundheit
ISIN/ Wkn:  IT0003828271 / A0EABR
Symbol/ Ticker:  RER1 (Frankfurt)
Kürzel:  FRA:RER1, ETR:RER1, RER1:GR
Index:  FTSEMIB
Webseite:  http://www.recordati.it/
Marktkapitalisierung:  11180 Mio. EUR
Umsatz:  2410 Mio. EUR
EBITDA:  866.63 Mio. EUR
Gewinn je Aktie:  2 EUR
Schulden:  2360 Mio. EUR
Liquide Mittel:  333.04 Mio. EUR
Umsatz-/ Gewinnwachstum:  11.9% / 1.2%
KGV/ KGV lG:  27.26 / 17.04
KUV/ KBV/ PEG:  4.72 / 5.67 / 1.77
Gewinnm./ Eigenkapitalr.:  17.32% / 22.02%
Dividende je Aktie:  1.27 EUR
Dividendenrendite/ -schätzung:  2.3% / 2.46%
Div. Historie:  19.05.25 - 0.67€
18.11.24 - 0.6€
>weitere anzeigen...
Insiderhandel:  -
Suchwörter:  RECORDATI
Letzte Datenerhebung:  05.07.25
>RECORDATI Eigentümer
Aktien: 205.76 Mio. St.
f.h. Aktien: 100.36 Mio. St.
Insider Eigner: 46.82%
Instit. Eigner: 28.58%
Leerverk. Aktien: -
>RECORDATI Peer Group

 
24.06.25 - 13:45
 Amarin inks licensing deal with Recordati for lead drug Vazkepa (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
24.06.25 - 13:09
 RECORDATI ANNOUNCES EXCLUSIVE LICENSING & SUPPLY AGREEMENT WITH AMARIN TO COMMERCIALIZE VAZKEPA® IN EUROPE (GlobeNewswire EN)
 
RECORDATI ANNOUNCES EXCLUSIVE LICENSING & SUPPLY AGREEMENT WITH AMARIN TO COMMERCIALIZE VAZKEPA® IN EUROPE...
24.06.25 - 13:03
 Amarin Announces Exclusive License and Supply Agreement with Recordati to Commercialize VAZKEPA® (Icosapent Ethyl) in Europe (GlobeNewswire EN)
 
-- Company to Streamline Global Operations, Resulting in Approximately $70 Million of Cost Savings Over Next 12 Months and Accelerated Path to Positive Cash Flow -- -- Conference Call Today at 8:00 a.m. EDT with Investor Materials Available at AdvancingAmarin.com --...
15.05.25 - 20:06
 RECORDATI: TO BE HIGHLIGHTED AT AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGY (AACE) ANNUAL MEETING--THE EXPANDED INDICATION FOR ISTURISA® (OSILODROSTAT) FOR THE TREATMENT OF ENDOGENOUS HYPERCORTISOLEMIA IN ADULT PATIENTS WITH CUSHING′S SYNDRO (PR Newswire)
 
ISTURISA® (osilodrostat) is a cortisol synthesis inhibitor that blocks the enzyme 11beta-hydroxylase to help normalize hypercortisolemia in Cushing's syndrome, a rare endocrine condition that can have significant impact on patients and their families The expanded indication is supported......
08.05.25 - 16:06
 Recordati reports Q1 results (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
08.05.25 - 12:27
 RECORDATI: STRONG MOMENTUM OF THE GROUP CONTINUES INTO THE FIRST QUARTER OF 2025 REVENUE +11.9%, EBITDA(1) +10.7%, ADJUSTED NET INCOME(2) +7.2% (GlobeNewswire EN)
 
Milan, 8th May 2025 – The Board of Directors of Recordati S.p.A. approved the Group's Interim Report as of 31st March 2025, representing additional voluntary financial reporting(7). The Report was prepared using the assessment, measurement and recognition criteria prescribed by international accounting standards (IFRS). The financial statements as of 31st March 2025 will be available by 15th May 2025 at the company's offices and on the company's website (www.recordati.it) and can also be viewed on the authorised storage system 1Info (www.1Info.it)....
29.04.25 - 12:12
 Italy′s Recordati Sees Tariff Volatility Fueling Dealmaking (Bloomberg)
 
Italian drugmaker Recordati SpA is on the lookout for acquisitions, saying market volatility and the impact of tariffs have created the potential for cheaper buyouts....
28.04.25 - 19:21
 RECORDATI: 2025-2027 THREE-YEAR PLAN APPROVED FY 2027 TARGETS OF REVENUE BETWEEN € 3,000 AND € 3,200 MILLION; EBITDA(1) BETWEEN € 1,140 AND € 1,225 MILLION; ADJUSTED NET INCOME(2) BETWEEN € 770 AND € 820 MILLION (GlobeNewswire EN)
 
RECORDATI: 2025-2027 THREE-YEAR PLAN APPROVED FY 2027 TARGETS OF REVENUE BETWEEN € 3,000 AND € 3,200 MILLION; EBITDA(1) BETWEEN € 1,140 AND € 1,225 MILLION; ADJUSTED NET INCOME(2) BETWEEN € 770 AND € 820 MILLION...
16.04.25 - 10:36
 RECORDATI: FDA GRANTS ISTURISA® (OSILODROSTAT) EXPANDED INDICATION FOR THE TREATMENT OF ENDOGENOUS HYPERCORTISOLEMIA IN PATIENTS WITH CUSHING′S SYNDROME (GlobeNewswire EN)
 
RECORDATI: FDA GRANTS ISTURISA® (OSILODROSTAT) EXPANDED INDICATION FOR THE TREATMENT OF ENDOGENOUS HYPERCORTISOLEMIA IN PATIENTS WITH CUSHING'S SYNDROME...
13.02.25 - 16:51
 Recordati reports prelim FY results and provides FY outlook (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
13.02.25 - 12:42
 RECORDATI: PRELIMINARY RESULTS FOR FULL YEAR 2024 REVENUE +12.4%, EBITDA(1) +12.5%, ADJUSTED NET INCOME(2) +8.4% PEAK YEAR SALES TARGETS RAISED FOR KEY RARE DISEASES PRODUCTS (GlobeNewswire EN)
 
RECORDATI: PRELIMINARY RESULTS FOR FULL YEAR 2024 REVENUE +12.4%, EBITDA(1) +12.5%, ADJUSTED NET INCOME(2) +8.4%PEAK YEAR SALES TARGETS RAISED FOR KEY RARE DISEASES PRODUCTS...
26.11.24 - 15:56
 Recordati investor CVC taps up potential buyers of drugs group, rival says (Reuters EN)
 
UPDATE 1-Recordati investor CVC taps up potential buyers of drugs group, rival says Adds background and quotes MILAN, Nov 26 (Reuters) - The main shareholder of Italy's Recordati RECI.MI is in contact with other Italian drugmakers over a possible sale, the chief executive of rival Dompe Farmaceutica told Reuters on Tuesday. Speculation about the future of Recordati increased over the summer after majority shareholder CVC Capital Partners hired investment banks JP Morgan JPM.N and Goldman Sachs G...
26.11.24 - 15:42
 Angelini Pharma Said to Discuss Combination With CVC′s Recordati (Bloomberg)
 
Um den gesamten Artikel unter news.google.com zu lesen, klicken Sie bitte auf die Überschrift...
26.11.24 - 15:26
 Angelini Pharma Said To Discuss Combination With CVC′S Recordati - Bloomberg News (Reuters EN)
 
BRIEF-Angelini Pharma Said To Discuss Combination With CVC'S Recordati - Bloomberg News Nov 26 (Reuters) - ANGELINI PHARMA SAID TO DISCUSS COMBINATION WITH CVC'S RECORDATI - BLOOMBERG NEWS Source text: https://tinyurl.com/4bh4v86v...
16.11.24 - 15:38
 XFRA : DIVIDEND/INTEREST INFORMATION - 18.11.2024 - IT0003828271 (XETRA)
 
Das Instrument RER1 IT0003828271 RECORDATI SPA EO -,125 EQUITY wird ex Dividende/Zinsen gehandelt am 18.11.2024 The instrument RER1 IT0003828271 RECORDATI SPA EO -,125 EQUITY has its ex-dividend/interest day on 18.11.2024...
08.11.24 - 12:12
 RECORDATI: CONTINUED DOUBLE-DIGIT GROWTH IN THE FIRST NINE MONTHS OF 2024 - REVENUE +12.0%, EBITDA(1) +11.8%, ADJUSTED NET INCOME(2) +9.5% (GlobeNewswire EN)
 
Milan, November 8th, 2024 – The Board of Directors of Recordati S.p.A. approved the Group's Interim Report on 30th September 2024, representing additional voluntary financial reporting (6). The Report was prepared using the assessment, measurement and recognition criteria prescribed by international accounting standards (IFRS). The Group's Interim Report dated 30th September 2024 will be available on 11th November at the company's offices and on the company's website (www.recordati.com) and can also be viewed on the authorized storage system 1Info (www.1Info.it)....
04.10.24 - 14:16
 Recordati looks for M&A deal in rare diseases, specialty, primary care sectors (Reuters EN)
 
Recordati looks for M&A deal in rare diseases, specialty, primary care sectors...
04.10.24 - 10:14
 Recordati buys rights to rare immune disorder drug from Sanofi for $825 mln (Reuters EN)
 
Recordati buys rights to rare immune disorder drug from Sanofi for $825 mln...
04.10.24 - 09:08
 Recordati kauft Sanofi Enjaymo-Rechte für 825 Millionen Dollar ab (Dow Jones)
 
Von Andrea Figueras BARCELONA (Dow Jones)--Das Pharmaunternehmen Recordati kauft Sanofi für 825 Millionen US-Dollar die weltweiten Rechte am Autoimmunpräparat Enjaymo ab. Die Vereinbarung ......
04.10.24 - 08:51
 Recordati to Buy Global Rights to Sanofi′s Enjaymo for $825 Million (Dow Jones EN)
 
Um den gesamten Artikel unter morningstar.com zu lesen, klicken Sie bitte auf die Überschrift...
>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!
Zitat des Tages: Männer sind wie Luft, zwar versaut, aber unentbehrlich. - Michelle Pfeiffer
Partner:    >Tradegate Börse | >Dukascopy | >Boersentreff- Partner

Börsentreff auf Facebook | Börsentreff auf X | Börsentreff auf Instagram

Copyright @ Boersentreff.de - Die Märkte im Blick!